首页|射干麻黄汤加减联合多索茶碱治疗支气管哮喘的临床研究

射干麻黄汤加减联合多索茶碱治疗支气管哮喘的临床研究

扫码查看
目的 探讨支气管哮喘患者联用射干麻黄汤、多索茶碱治疗的效果.方法 依据用药方案,选取宁夏银川市永宁县中医医院84例支气管哮喘患者为研究对象,分为2组,39例以多索茶碱展开治疗为西药组,45例以多索茶碱展开治疗的同时应用射干麻黄汤为中西组,对比2组的疗效.结果 治疗后,中西组中医症候积分显著较西药组低,中西组最大呼气速流(PEF)、1秒钟用力呼气量(FEV1)、外周血嗜酸粒细胞(ESO)改善程度明显较西药组优越,且中西组总有效率是95.56%,高于西药组的76.92%,2组比较差异均具有统计学意义(P<0.05);不良反应方面,2组比较差异无统计学意义.结论 对于支气管哮喘患者,于多索茶碱展开治疗的同时,应用射干麻黄汤可促进疗效的提升,使患者肺功能、炎性症状得到显著改善,且不良反应不会增加.
Clinical study of treatment of bronchial asthma by the combination of salicyloxanine tonga decoction combined with dosobromine
Objective To explore the effect of combined treatment of the combined treatment of bronchial asthma with the combined treatment of dried ephedrine and doxyline. Methods According to the regimen, divide 84 patients with bronchial asthma for two groups, 39 cases with doxofylline treatment of western medicine group, 45 cases in doxofylline treatment at the same time correlation dry ephedra soup for application for group of Chinese and western, compared two groups of curative effect. Results After treatment, the group of Chinese and western of TCM symptom score was significantly lower than western medicine group, the group of Chinese and western PEF, FEV1, ESO improved significantly compared with western medicine group is superior, and the Chinese and western group total effective rate is 95.56 %, contrast to 76.92 % of the western medicine group was significantly higher, the differences between the two groups were statistically significant (P<0.05). on the side of adverse reactions, the two groups showed no significant differences. Conclusion For patients with bronchial asthma, to doxofylline the treatment of at the same time, the correlation of dry ephedra soup for application can promote the ascension of curative effect, make the patients' lung function, inflammatory symptoms improved significantly, and will not increase adverse reactions.

bronchial asthmashot dry ephedradoxofylline

徐如平、吴自平、徐静

展开 >

宁夏银川市永宁县中医医院 中医科,宁夏 银川 750100

支气管哮喘 射干麻黄汤 多索茶碱

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 13
  • 10